Bisacodyl

Summary

Bisacodyl (CHEMBL942) is an approved small molecule (ATC A06AB02); indicated across 2 conditions including constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A06AB02 (+2 more)
• Indications: 2 conditions
• Clinical trials: 48
• Chemistry: 361.4 Da · C22H19NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL942
Name	Bisacodyl
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2391
ATC	A06AB02, A06AG02, A06AB52
Molecular formula	C22H19NO4
Molecular weight	361.4
InChIKey	KHOITXIGCFIULA-UHFFFAOYSA-N

SMILES: CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3

IUPAC name: [4-[(4-acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate

Also known as: Biolax, Bisacodilo, Bisacodyl, Bisacodyl component of halflytely, Correctol tablets, caplets, Dulcodos, Dulcolax, Entrolax, Evac-q-tabs, Feen-a-mint tablets, Modane

Patent coverage: 4,626 distinct patent families (14,654 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,647 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: G-protein coupled receptor 55, Lysine-specific demethylase 4E, Prelamin-A/C, Alpha-2A adrenergic receptor, Thyrotropin receptor, Estrogen receptor, Alpha-1A adrenergic receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, 3’,5’-cyclic-AMP phosphodiesterase 4A, Cytochrome P450 2C9, Cytochrome P450 3A4, Hypoxia-inducible factor 1-alpha, Lethal factor, Signal transducer and activator of transcription 6, Bile salt export pump.

Bioactivity

ChEMBL activities: 27 potent at pChembl ≥ 5 of 37 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15917	6.8	Potency	158.5	nM	CHEMBL_ACT_4633115
STAT6	6.4	Potency	398.1	nM	CHEMBL_ACT_4711860
STAT6	6.4	Potency	398.1	nM	CHEMBL_ACT_4897979
SLC6A3	6.35	AC50	450	nM	CHEMBL_ACT_25125082
HIF1A	6.3	Potency	501.2	nM	CHEMBL_ACT_4130602
HIF1A	6.3	Potency	501.2	nM	CHEMBL_ACT_4518879
P15917	6.2	Potency	631	nM	CHEMBL_ACT_4633311
HIF1A	6.1	Potency	794.3	nM	CHEMBL_ACT_4131768
HIF1A	6.1	Potency	794.3	nM	CHEMBL_ACT_4519291
GPR55	6.04	IC50	908.4	nM	CHEMBL_ACT_5664506
OPRK1	6.01	Ki	975	nM	CHEMBL_ACT_7609626
TSHR	5.9	Potency	1259	nM	CHEMBL_ACT_3923030
TSHR	5.9	Potency	1259	nM	CHEMBL_ACT_4619587
LMNA	5.85	Potency	1412	nM	CHEMBL_ACT_3621567
SLC6A3	5.76	Ki	1755	nM	CHEMBL_ACT_7608361
SLC6A3	5.66	IC50	2208	nM	CHEMBL_ACT_7608360
OPRK1	5.61	IC50	2437	nM	CHEMBL_ACT_7609625
TSHR	5.6	Potency	2512	nM	CHEMBL_ACT_3924703
TSHR	5.6	Potency	2512	nM	CHEMBL_ACT_4619516
ADRA2A	5.26	AC50	5470	nM	CHEMBL_ACT_25156552
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_4989535
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_5054727
CYP3A4	5.1	AC50	7943	nM	CHEMBL_ACT_6049528
ESR1	5.05	AC50	8850	nM	CHEMBL_ACT_25138981
ADRA1A	5.05	AC50	8850	nM	CHEMBL_ACT_25218955
LMNA	5	Potency	10000	nM	CHEMBL_ACT_3647833
CYP2C9	5	IC50	10000	nM	CHEMBL_ACT_7608344

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 48.

Phase distribution

Phase	Trials
PHASE4	21
Not specified	11
PHASE3	10
PHASE2	3
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06455813	PHASE4	RECRUITING	What Laxative Should be Used After Hip Fracture Surgery?
NCT07351357	PHASE4	NOT_YET_RECRUITING	Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter)
NCT00509327	PHASE4	COMPLETED	Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery
NCT00857272	PHASE4	COMPLETED	F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects
NCT00953017	PHASE4	COMPLETED	A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy
NCT01063049	PHASE4	COMPLETED	Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation
NCT01510977	PHASE4	TERMINATED	Second Bowel Preparation for Colonoscopy Failure
NCT01531140	PHASE4	COMPLETED	PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy
NCT01627171	PHASE4	UNKNOWN	Colonoscopy Preparation Optimization for INpatients- COIN Study
NCT01773096	PHASE4	COMPLETED	Methylnaltrexone Use for Opioid-induced Postoperative Constipation
NCT01853709	PHASE4	UNKNOWN	Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients
NCT01865916	PHASE4	COMPLETED	2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation
NCT01879605	PHASE4	COMPLETED	Study About Effect of Preoperative Bowel Preparation Versus no Bowel Preparation Before Spinal Surgery
NCT01887158	PHASE4	COMPLETED	Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection
NCT01917773	PHASE4	COMPLETED	Effect of Octreotide on the Colonic Motility in Pediatric Patients
NCT02040285	PHASE4	COMPLETED	Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)
NCT02386449	PHASE4	COMPLETED	A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy
NCT02415569	PHASE4	COMPLETED	Tailored Bowel Preparation According to Bristol Stool Form Scale
NCT03279341	PHASE4	COMPLETED	Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects
NCT04129788	PHASE4	COMPLETED	MRI Assessment of Mode of Action of Bisacodyl, Multiple Doses
NCT04132661	PHASE4	COMPLETED	MRI Assessment of Mode of Action of Bisacodyl, Single Dose
NCT00526097	PHASE3	COMPLETED	Dulcolax vs Placebo in Functional Constipation
NCT01073930	PHASE3	COMPLETED	Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep
NCT01073943	PHASE3	COMPLETED	Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep
NCT01655095	PHASE3	COMPLETED	Improving Bowel Preparation for the Colon Capsule
NCT01745835	PHASE3	COMPLETED	Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation
NCT01982240	PHASE3	COMPLETED	12-Week Study of Plecanatide for CIC (The CIC3 Study)
NCT02211976	PHASE3	COMPLETED	Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness
NCT02976805	PHASE3	COMPLETED	Multi-centre Failed Bowel Prep RCT
NCT02980562	PHASE3	COMPLETED	Comparison of Low Volume PEG-Asc and Lower Volume PEG-Asc With Bisacodyl
NCT05144295	PHASE3	COMPLETED	Lubiprostone for Functional Constipation in the Under 18 Years Patients
NCT01011426	PHASE2	COMPLETED	Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients
NCT01044394	PHASE2	WITHDRAWN	Same-day, Reduced Volume Bowel Preparation
NCT02609607	PHASE2	TERMINATED	Treating Anorectal Dysfunction in MS
NCT02211911	PHASE1	COMPLETED	Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females
NCT05409157	PHASE1	COMPLETED	A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants
NCT07127237	EARLY_PHASE1	NOT_YET_RECRUITING	Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults
NCT04903470	Not specified	RECRUITING	Defecation Patterns in Constipated Patients
NCT06335797	Not specified	RECRUITING	Optimization of Postoperative Bowel Habits
NCT01452737	Not specified	WITHDRAWN	Comparing 4L Golytely to 2L Golytely With 15mg Bisacodyl Regimens for Inpatient Colonic Preparation
NCT01533688	Not specified	COMPLETED	Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients
NCT02383758	Not specified	COMPLETED	An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT02481219	Not specified	COMPLETED	Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure
NCT03226145	Not specified	UNKNOWN	Reclassifying Constipation Using Imaging and Manometry
NCT03247595	Not specified	COMPLETED	Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy
NCT03248726	Not specified	COMPLETED	Comparing Single-dose Low-volume PEG Plus Bisacodyl vs. Split-dose PEG for Bowel Preparation in Morning Colonoscopy
NCT04930237	Not specified	WITHDRAWN	RELISTOR’s Effects on Opioid-Induced Constipation
NCT05032794	Not specified	COMPLETED	Unrestricted Diet for Screening Colonoscopy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).